PhylloTech is a biotechnology company that has developed an innovative plant-based biomanufacturing platform using tobacco plants. The company's technology allows for the production of valuable proteins and compounds through genetic engineering of tobacco plants. PhylloTech's approach involves targeting protein production to trichome glands on the surface of tobacco leaves, enabling both production and purification of desired proteins without destroying the plant. This non-destructive process allows for continuous harvesting, as proteins can be collected by simply washing the leaf surfaces. In 2012, PhylloTech successfully bioengineered tobacco plants to produce spider silk proteins, demonstrating the potential of their platform for manufacturing hard-to-produce technical proteins. The company has since expanded its focus to biopharmaceutical production, including monoclonal antibodies for treating Ebola virus. PhylloTech's engineered plants can reportedly yield Ebola virus monoclonal antibodies at up to 98% purity with minimal purification steps when grown under controlled conditions. This "green factory" system is capable of producing fresh commercial batches of biopharmaceuticals every 10 days.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.